Page results
-
A patient with motor neurone disease was able to control a computer just by using his thoughts following the UK’s first Neuralink implant surgery at UCLH’s National Hospital for Neurology and Neurosurgery (NHNN) in October 2025.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
Proposals to relocate Mount Vernon Cancer Centre to Watford, with UCLH as the preferred provider, have moved a step closer with funding agreed and the start of a public consultation.
-
Initial results from an early phase study testing the safety and efficacy of a new drug for multiple myeloma have shown a 100 per cent overall response rate in patients with recurrent disease who were given the clinically recommended dose of the investigational drug.
-
One of the FOIA Code of Practice requirements is for public authorities to publish more information about their performance in handling FOIA requests.
-
Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.
-
A pioneering breast cancer therapy developed by UCLH and UCL, which requires just one shot of radiotherapy rather than conventional weeks-long treatment, has proven to be as effective for most women in treating the disease.
-
As World Lung Cancer Day approaches (1 August) the SUMMIT Study reports that it has made great strides in catching up with patients whose nodule follow ups were cancelled due to COVID-19.
-
How UCLH uses clinical data in research.
-
Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.
File results
-
FOI/2023/0099 - Number of autoclaves used at Trust
-
FOI/2021/0284 - Sleep respiratory service
-
FOI/2023/0086 - Number/ wait times for MRI scans for multiple sclerosis/ dementia/ prostate/ pancreatic cancer
-
FOI/2023/0083 - Software systems/ suppliers used at Trust
-
FOI/2023/0082 - Organisation structure for Performance and Planning department
-
FOI/2023/0081 - Biometric technology wearables/ data collection
-
FOI/2023/0080 - Treatment for Myeloid leukaemia (AML) and chronic lymphocytic leukaemia
-
FOI/2023/0075 - Attrition rates for staff working in advanced practice roles
-
FOI/2023/0073 - Telephony and UC/ collaboration, Microsoft 365 licence and on-premise or cloud storage
-
FOI/2023/0041 - International recruitment